APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biosimilar Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchBiosimilar Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biosimilar market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biosimilar market include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biosimilar market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilar and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilar revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biosimilar market.

Biosimilar Segment by Company

Qilu Pharmaceutical

Bio-Thera

Zhejiang Hisun

Shanghai Henlius

Innovent Biologics

Jiangsu Hengrui

Gan&Lee

Tonghua Dongbao

United Laboratory

3SBIO

Luye Pharma

Biosimilar Segment by Type

Biosimilar Monoclonal Antibodies

Biosimilar Insulin

Others

Biosimilar Segment by Application

Cancer

Immunological Diseases

Diabetes

Others

Biosimilar Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biosimilar status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biosimilar key companies, revenue, market share, and recent developments.

3. To split the Biosimilar breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biosimilar market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biosimilar significant trends, drivers, influence factors in global and regions.

6. To analyze Biosimilar competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilar industry.

Chapter 3: Detailed analysis of Biosimilar company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biosimilar in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biosimilar Industry Trends Table 2. Biosimilar Industry Drivers Table 3. Biosimilar Industry Opportunities and Challenges Table 4. Biosimilar Industry Restraints Table 5. Global Biosimilar Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biosimilar Revenue Share by Company (2021-2026) Table 7. Global Biosimilar Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biosimilar Key Company Manufacturing Base & Headquarters Table 9. Global Biosimilar Company, Product Type & Application Table 10. Global Biosimilar Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Biosimilar Monoclonal Antibodies Table 15. Significant Companies of Biosimilar Insulin Table 16. Significant Companies of Others Table 17. Global Biosimilar Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Biosimilar Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Biosimilar Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Biosimilar Sales Value Share by Type (2021-2026) Table 21. Global Biosimilar Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Cancer Table 23. Significant Companies of Immunological Diseases Table 24. Significant Companies of Diabetes Table 25. Significant Companies of Others Table 26. Global Biosimilar Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Biosimilar Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Biosimilar Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Biosimilar Sales Value Share by Application (2021-2026) Table 30. Global Biosimilar Sales Value Share by Application (2027-2032) Table 31. Global Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Biosimilar Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Biosimilar Sales Value Share by Region (2021-2026) Table 34. Global Biosimilar Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Biosimilar Sales Value Share by Region (2027-2032) Table 36. Global Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Biosimilar Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Biosimilar Sales Value Market Share by Country (2021-2026) Table 39. Global Biosimilar Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Biosimilar Sales Value Market Share by Country (2027-2032) Table 41. Qilu Pharmaceutical Company Information Table 42. Qilu Pharmaceutical Business Overview Table 43. Qilu Pharmaceutical Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Qilu Pharmaceutical Biosimilar Product Portfolio Table 45. Qilu Pharmaceutical Recent Development Table 46. Bio-Thera Company Information Table 47. Bio-Thera Business Overview Table 48. Bio-Thera Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Bio-Thera Biosimilar Product Portfolio Table 50. Bio-Thera Recent Development Table 51. Zhejiang Hisun Company Information Table 52. Zhejiang Hisun Business Overview Table 53. Zhejiang Hisun Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Zhejiang Hisun Biosimilar Product Portfolio Table 55. Zhejiang Hisun Recent Development Table 56. Shanghai Henlius Company Information Table 57. Shanghai Henlius Business Overview Table 58. Shanghai Henlius Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Shanghai Henlius Biosimilar Product Portfolio Table 60. Shanghai Henlius Recent Development Table 61. Innovent Biologics Company Information Table 62. Innovent Biologics Business Overview Table 63. Innovent Biologics Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Innovent Biologics Biosimilar Product Portfolio Table 65. Innovent Biologics Recent Development Table 66. Jiangsu Hengrui Company Information Table 67. Jiangsu Hengrui Business Overview Table 68. Jiangsu Hengrui Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Jiangsu Hengrui Biosimilar Product Portfolio Table 70. Jiangsu Hengrui Recent Development Table 71. Gan&Lee Company Information Table 72. Gan&Lee Business Overview Table 73. Gan&Lee Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Gan&Lee Biosimilar Product Portfolio Table 75. Gan&Lee Recent Development Table 76. Tonghua Dongbao Company Information Table 77. Tonghua Dongbao Business Overview Table 78. Tonghua Dongbao Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Tonghua Dongbao Biosimilar Product Portfolio Table 80. Tonghua Dongbao Recent Development Table 81. United Laboratory Company Information Table 82. United Laboratory Business Overview Table 83. United Laboratory Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. United Laboratory Biosimilar Product Portfolio Table 85. United Laboratory Recent Development Table 86. 3SBIO Company Information Table 87. 3SBIO Business Overview Table 88. 3SBIO Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. 3SBIO Biosimilar Product Portfolio Table 90. 3SBIO Recent Development Table 91. Luye Pharma Company Information Table 92. Luye Pharma Business Overview Table 93. Luye Pharma Biosimilar Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Luye Pharma Biosimilar Product Portfolio Table 95. Luye Pharma Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Biosimilar Product Image Figure 2. Global Biosimilar Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Biosimilar Monoclonal Antibodies Image Figure 8. Biosimilar Insulin Image Figure 9. Others Image Figure 10. Global Biosimilar Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Biosimilar Sales Value Share by Type (2021-2032) Figure 13. Cancer Image Figure 14. Immunological Diseases Image Figure 15. Diabetes Image Figure 16. Others Image Figure 17. Global Biosimilar Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Biosimilar Sales Value Share by Application (2021-2032) Figure 20. Global Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Biosimilar Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 23. North America Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 29. South America Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Biosimilar Monoclonal Antibodies
  • Biosimilar Insulin
  • Others
Applications
  • Cancer
  • Immunological Diseases
  • Diabetes
  • Others
Companies covered
  • Qilu Pharmaceutical
  • Bio-Thera
  • Zhejiang Hisun
  • Shanghai Henlius
  • Innovent Biologics
  • Jiangsu Hengrui
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory
  • 3SBIO
  • Luye Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biosimilar Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biosimilar Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biosimilar Market Dynamics
  1. 2.1 Biosimilar Industry Trends
  2. 2.2 Biosimilar Industry Drivers
  3. 2.3 Biosimilar Industry Opportunities and Challenges
  4. 2.4 Biosimilar Industry Restraints
3 Biosimilar Market by Company
  1. 3.1 Global Biosimilar Company Revenue Ranking in 2025
  2. 3.2 Global Biosimilar Revenue by Company (2021-2026)
  3. 3.3 Global Biosimilar Company Ranking (2024-2026)
  4. 3.4 Global Biosimilar Company Manufacturing Base and Headquarters
  5. 3.5 Global Biosimilar Company Product Type and Application
  6. 3.6 Global Biosimilar Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biosimilar Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biosimilar Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biosimilar Market by Type
  1. 4.1 Biosimilar Type Introduction
  2. 4.1.1 Biosimilar Monoclonal Antibodies
  3. 4.1.2 Biosimilar Insulin
  4. 4.1.3 Others
  5. 4.2 Global Biosimilar Sales Value by Type
  6. 4.2.1 Global Biosimilar Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Biosimilar Sales Value by Type (2021-2032)
  8. 4.2.3 Global Biosimilar Sales Value Share by Type (2021-2032)
5 Biosimilar Market by Application
  1. 5.1 Biosimilar Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Immunological Diseases
  4. 5.1.3 Diabetes
  5. 5.1.4 Others
  6. 5.2 Global Biosimilar Sales Value by Application
  7. 5.2.1 Global Biosimilar Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Biosimilar Sales Value by Application (2021-2032)
  9. 5.2.3 Global Biosimilar Sales Value Share by Application (2021-2032)
6 Biosimilar Regional Value Analysis
  1. 6.1 Global Biosimilar Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilar Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biosimilar Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biosimilar Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biosimilar Sales Value (2021-2032)
  7. 6.3.2 North America Biosimilar Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biosimilar Sales Value (2021-2032)
  10. 6.4.2 Europe Biosimilar Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biosimilar Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biosimilar Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biosimilar Sales Value (2021-2032)
  16. 6.6.2 South America Biosimilar Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biosimilar Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biosimilar Sales Value Share by Country, 2025 VS 2032
7 Biosimilar Country-level Value Analysis
  1. 7.1 Global Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biosimilar Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biosimilar Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biosimilar Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biosimilar Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biosimilar Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biosimilar Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biosimilar Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biosimilar Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biosimilar Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biosimilar Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biosimilar Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biosimilar Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biosimilar Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biosimilar Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biosimilar Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biosimilar Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biosimilar Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biosimilar Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biosimilar Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biosimilar Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biosimilar Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biosimilar Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biosimilar Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biosimilar Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biosimilar Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biosimilar Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biosimilar Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biosimilar Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biosimilar Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biosimilar Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biosimilar Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biosimilar Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biosimilar Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biosimilar Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biosimilar Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biosimilar Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biosimilar Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biosimilar Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biosimilar Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biosimilar Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biosimilar Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biosimilar Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biosimilar Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biosimilar Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biosimilar Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biosimilar Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biosimilar Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biosimilar Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biosimilar Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biosimilar Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biosimilar Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biosimilar Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biosimilar Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biosimilar Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biosimilar Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biosimilar Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biosimilar Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biosimilar Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biosimilar Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biosimilar Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biosimilar Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biosimilar Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biosimilar Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biosimilar Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biosimilar Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biosimilar Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biosimilar Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biosimilar Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biosimilar Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biosimilar Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biosimilar Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biosimilar Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biosimilar Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biosimilar Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biosimilar Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biosimilar Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biosimilar Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biosimilar Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biosimilar Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biosimilar Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biosimilar Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biosimilar Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biosimilar Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biosimilar Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biosimilar Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biosimilar Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biosimilar Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Qilu Pharmaceutical
  2. 8.1.1 Qilu Pharmaceutical Company Information
  3. 8.1.2 Qilu Pharmaceutical Business Overview
  4. 8.1.3 Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Qilu Pharmaceutical Biosimilar Product Portfolio
  6. 8.1.5 Qilu Pharmaceutical Recent Developments
  7. 8.2 Bio-Thera
  8. 8.2.1 Bio-Thera Company Information
  9. 8.2.2 Bio-Thera Business Overview
  10. 8.2.3 Bio-Thera Biosimilar Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bio-Thera Biosimilar Product Portfolio
  12. 8.2.5 Bio-Thera Recent Developments
  13. 8.3 Zhejiang Hisun
  14. 8.3.1 Zhejiang Hisun Company Information
  15. 8.3.2 Zhejiang Hisun Business Overview
  16. 8.3.3 Zhejiang Hisun Biosimilar Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zhejiang Hisun Biosimilar Product Portfolio
  18. 8.3.5 Zhejiang Hisun Recent Developments
  19. 8.4 Shanghai Henlius
  20. 8.4.1 Shanghai Henlius Company Information
  21. 8.4.2 Shanghai Henlius Business Overview
  22. 8.4.3 Shanghai Henlius Biosimilar Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Henlius Biosimilar Product Portfolio
  24. 8.4.5 Shanghai Henlius Recent Developments
  25. 8.5 Innovent Biologics
  26. 8.5.1 Innovent Biologics Company Information
  27. 8.5.2 Innovent Biologics Business Overview
  28. 8.5.3 Innovent Biologics Biosimilar Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Innovent Biologics Biosimilar Product Portfolio
  30. 8.5.5 Innovent Biologics Recent Developments
  31. 8.6 Jiangsu Hengrui
  32. 8.6.1 Jiangsu Hengrui Company Information
  33. 8.6.2 Jiangsu Hengrui Business Overview
  34. 8.6.3 Jiangsu Hengrui Biosimilar Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Biosimilar Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Recent Developments
  37. 8.7 Gan&Lee
  38. 8.7.1 Gan&Lee Company Information
  39. 8.7.2 Gan&Lee Business Overview
  40. 8.7.3 Gan&Lee Biosimilar Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gan&Lee Biosimilar Product Portfolio
  42. 8.7.5 Gan&Lee Recent Developments
  43. 8.8 Tonghua Dongbao
  44. 8.8.1 Tonghua Dongbao Company Information
  45. 8.8.2 Tonghua Dongbao Business Overview
  46. 8.8.3 Tonghua Dongbao Biosimilar Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Tonghua Dongbao Biosimilar Product Portfolio
  48. 8.8.5 Tonghua Dongbao Recent Developments
  49. 8.9 United Laboratory
  50. 8.9.1 United Laboratory Company Information
  51. 8.9.2 United Laboratory Business Overview
  52. 8.9.3 United Laboratory Biosimilar Revenue and Gross Margin (2021-2026)
  53. 8.9.4 United Laboratory Biosimilar Product Portfolio
  54. 8.9.5 United Laboratory Recent Developments
  55. 8.10 3SBIO
  56. 8.10.1 3SBIO Company Information
  57. 8.10.2 3SBIO Business Overview
  58. 8.10.3 3SBIO Biosimilar Revenue and Gross Margin (2021-2026)
  59. 8.10.4 3SBIO Biosimilar Product Portfolio
  60. 8.10.5 3SBIO Recent Developments
  61. 8.11 Luye Pharma
  62. 8.11.1 Luye Pharma Company Information
  63. 8.11.2 Luye Pharma Business Overview
  64. 8.11.3 Luye Pharma Biosimilar Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Luye Pharma Biosimilar Product Portfolio
  66. 8.11.5 Luye Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst